Sarizotan Hydrochloride

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSarizotan Hydrochloride
Drug Alias Name沙利佐坦Sarizotan沙立佐坦Sarizotanum沙立佐坦盐酸盐 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsDopamine D2 receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorDopamine D2 receptor
Therapy Area/IndicationsRett SyndromeDyskinesiasParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmd Serono IncNational Institute Of Neurological Disorders And StrokeNewron Pharmaceuticals Spa
Active IndicationsN/A
Inactive IndicationsRett SyndromeDyskinesiasParkinson Disease

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG